Varian Medical Systems Stock Hits New 52-Week High (VAR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Varian Medical Systems (NYSE: VAR) hit a new 52-week high Monday as it is currently trading at $73.90, above its previous 52-week high of $73.87 with 665,829 shares traded as of 12:46 p.m. ET. Average volume has been 971,100 shares over the past 30 days.

Varian Medical Systems has a market cap of $8.04 billion and is part of the health care sector and health services industry. Shares are up 4.9% year to date as of the close of trading on Friday.

Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software for treating cancer with radiotherapy, radiosurgery, proton therapy, and brachytherapy worldwide. The company has a P/E ratio of 19.6, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Varian Medical Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Varian Medical Systems Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

PerkinElmer Takes Cautious Approach to M&A

Here's How Health-Care Reform Will Affect This Cancer Care Company

Corporate Tax Reform Could Be a Bigger Deal for This Company Than the ACA

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

PerkinElmer Medical Imaging Unit Sale Could Be in the Works